Axa’s NovoCure NVCR Stock Holding History

Axa’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-371,773	Closed	-$6.62M	–	722
2025 Q2	$6.62M	Buy	371,773 +96,579	+35%	+$1.68M	0.02%	495
2025 Q1	$4.9M	Buy	+275,194	New	+$6.25M	0.02%	544
2022 Q3	–	Sell	-10,296	Closed	-$716K	–	1181
2022 Q2	$716K	Buy	10,296 +96	+0.9%	+$7.23K	﹤0.01%	922
2022 Q1	$845K	Buy	+10,200	New	+$751K	﹤0.01%	975
2021 Q4	–	Sell	-5,500	Closed	-$639K	–	1250
2021 Q3	$639K	Hold	5,500	–	–	﹤0.01%	1032
2021 Q2	$1.22M	Sell	5,500 -11,300	-67%	-$2.2M	﹤0.01%	969
2021 Q1	$2.22M	Sell	16,800 -47,800	-74%	-$7.56M	0.01%	830
2020 Q4	$11.2M	Buy	64,600 +23,600	+58%	+$3.23M	0.04%	484
2020 Q3	$4.56M	Buy	41,000 +31,800	+346%	+$2.54M	0.02%	650
2020 Q2	$546K	Sell	9,200 -18,300	-67%	-$1.2M	﹤0.01%	1046
2020 Q1	$1.85M	Sell	27,500 -28,000	-50%	-$2.21M	0.01%	752
2019 Q4	$4.68M	Sell	55,500 -22,000	-28%	-$1.78M	0.02%	638
2019 Q3	$5.79M	Buy	77,500 +14,700	+23%	+$1.18M	0.02%	602
2019 Q2	$3.97M	Sell	62,800 -4,600	-7%	-$233K	0.02%	711
2019 Q1	$3.25M	Buy	67,400 +21,000	+45%	+$1.01M	0.01%	759
2018 Q4	$1.55M	Buy	46,400 +30,500	+192%	+$1.12M	0.01%	873
2018 Q3	$833K	Sell	15,900 -8,700	-35%	-$346K	﹤0.01%	1069
2018 Q2	$770K	Hold	24,600	–	–	﹤0.01%	1064
2018 Q1	$536K	Buy	+24,600	New	+$529K	﹤0.01%	1146

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's NVCR Position: Q3 2025 in Review

Axa sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 371,773 shares — an estimated $6.62M sold.

Axa first reported a position in NVCR in Q1 2018 and held it in 19 quarters. The position peaked at $11.2M in Q4 2020. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

Axa reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
Axa sold 371,773 NovoCure shares in Q3 2025, an estimated $6.62M.
Axa first reported a position in NovoCure in Q1 2018 and held it in 19 quarters.
Axa's NovoCure position peaked at $11.2M in Q4 2020.
244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.